ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic restructuring, introducing two new divisions: Medical and Supplement. The Medical Division will focus on a clinic for Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis patients. The Supplement Division aims to acquire or invest in companies producing organic supplements using US manufacturing processes.
CEO Larry Powalisz stated that this restructuring reflects ADIA's commitment to innovation and meeting evolving consumer demands. The company believes these new divisions will drive growth and positively impact individuals' lives. ADIA Nutrition Inc. aims to reinforce its position as a trailblazer in the nutrition industry through this strategic move.